Studies in patient samples and cell culture suggest let-7c, miR-99a and miR-125b could serve as prognostic markers in patients with estrogen receptor–positive luminal breast cancers.

Genomewide association studies identified four genes that could serve as diagnostic markers and/or therapeutic targets for EoE.

miRNA-targeted antimiRs conjugated to a peptide with a low pH–induced transmembrane structure (pHLIP) could help treat solid tumors.

siRNNs could enable RNAi knockdown of therapeutic targets in a broader range of cells and tissue types than siRNA.

Fusing therapeutic proteins to affibodies with pH-dependent binding to neonatal Fc receptor could improve the proteins' half-lives.

A high throughput, miniaturized chemical synthesis platform could enable rapid discovery of lead compounds.

In vitro and rat studies suggest inhibiting the enzymatic activity of house dust mite (HDM) allergens could help treat allergic asthma.

Cell and mouse studies have identified pentacyclic triterpenoid analogs that could help treat influenza infections and have lower risk for resistance than amantadine.

Mouse studies suggest enhancing persistent IgE responses could help prevent GI infection with parasitic worms.

In vitro studies have identified indolylarylsulfone derivatives that could help treat HIV infection.

Mouse studies suggest inhibiting ferroptosis could help treat ischemia/reperfusion injury in the liver and kidney.

Mouse studies suggest inhibiting PGF could help treat hypertension.

In vitro and rodent studies suggest ophiopogonin D could help prevent doxorubicin-induced cardiotoxicity.

Mouse studies suggest inhibiting SORT1 in macrophages and T cells could help treat atherosclerosis.

Mouse and cell culture studies suggest inhibiting TOPBP1 could help treat cancer.

Mouse studies suggest chemically modified carbohydrate conjugates could be useful as antigens for the development of cancer vaccines.

Tumor cell and mouse studies suggest tetravalent antibodies that target four different antigens could help treat cancers resistant to HER-targeted therapies.

In vitro and mouse studies suggest THZ1, a covalent CDK7 inhibitor, could help treat neuroblastoma and other cancers driven by MYCN and other c-MYC (MYC)-family oncoproteins.

In vitro and mouse studies suggest inhibiting TRIM37 could help treat breast cancer.

Studies in mice and human samples suggest inhibiting LYN could help treat estrogen receptor–positive breast cancers resistant to anti-estrogen therapy.

Genocea has identified an immunological imprint in patients with malaria and is using a $1.2 million grant from the Gates Foundation to turn the findings into a vaccine.

Heidelberg Pharma has resuscitated a long-dead ADC toxin with updated conjugation techniques, and its partner Roche has thrown the company a lifeline that could help validate the platform.

Yabao and MRC Technology partner in PD; charities form Neuro-MAP to insource pharma's abandoned compounds; Singapore creates a diagnostic hub; a roundup of public-private partnerships.

Moving discoveries from academia to industry requires a delicate balance of risk, reward, skill sets and personalities, according to a translational panel held at BIO-Europe's partnering conference.

The siRNN technology that Solstice licensed from UCSD could take RNAi-based therapies to tissues outside the liver and expand their use to a host of new diseases.